drugset / Trial / NCT05111860
Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
NaSingle-groupOpen-labelTreatment
Summary
Prospectively Investigate the effectiveness and safety of neoadjuvant Bevacizumab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS mutant-type locally advanced rectal cancer
Timeline
- Start
- 2022-11-01
- Primary completion
- 2024-08-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 5-Fluorouridine | Small molecule | 400 mg/m2 | — |
| Subject | 5-Fluorouridine | Small molecule | 2400 mg/m2 | — |
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Calcium folinate | Unknown | 400 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |